The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 361:533-535 July 30, 2009 Number 5
NextNext

Telaprevir for Chronic HCV Infection

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Hoofnagle, J. H.
-Related Article
by McHutchison, J. G.
-Related Article
by Hézode, C.
-PubMed Citation
To the Editor: McHutchison et al. and Hézode et al. (April 30 issue) found an important effect of adding telaprevir to current antiviral therapy.1,2 Nevertheless, the results of the Protease Inhibition for Viral Evaluation (PROVE) trials (ClinicalTrials.gov numbers, NCT00336479 [ClinicalTrials.gov] and NCT00372385 [ClinicalTrials.gov] ) are disappointing, since they demonstrate the risk of serious side effects resulting from high dosing of a new molecule, with profound consequences for efficacy. Combined data from all telaprevir regimens in both trials show a significant difference in sustained virologic response between patients completing and those discontinuing treatment (78% and 25%, respectively; P<0.001). Although telaprevir had an acceptable . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.